Abstract
Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinical models of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g., through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery and optimization including computational and bioinformatics tools and novel experimental techniques.
Keywords: Angiogenesis, animal model, computational biology, inhibitor, in vitro model, peptidomimetics, tumor vasculature, tumor, angiogenesis-dependent diseases, microvessel formation, cancer, anti-angiogenic peptides, non-natural amino acid substitutions, anti-cancer agents
Current Pharmaceutical Biotechnology
Title: Anti-Angiogenic Peptides for Cancer Therapeutics
Volume: 12 Issue: 8
Author(s): Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz and Aleksander S. Popel
Affiliation:
Keywords: Angiogenesis, animal model, computational biology, inhibitor, in vitro model, peptidomimetics, tumor vasculature, tumor, angiogenesis-dependent diseases, microvessel formation, cancer, anti-angiogenic peptides, non-natural amino acid substitutions, anti-cancer agents
Abstract: Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinical models of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g., through L-to-D and non-natural amino acid substitutions. We highlight technological advances in peptide discovery and optimization including computational and bioinformatics tools and novel experimental techniques.
Export Options
About this article
Cite this article as:
V. Rosca Elena, E. Koskimaki Jacob, G. Rivera Corban, B. Pandey Niranjan, P. Tamiz Amir and S. Popel Aleksander, Anti-Angiogenic Peptides for Cancer Therapeutics, Current Pharmaceutical Biotechnology 2011; 12 (8) . https://dx.doi.org/10.2174/138920111796117300
DOI https://dx.doi.org/10.2174/138920111796117300 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Trimethylamine: Metabolic, Pharmacokinetic and Safety Aspects
Current Drug Metabolism Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks
Current Medicinal Chemistry GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Current Topics in Medicinal Chemistry The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Collagen: The Oldest Scaffold for Tissue Regeneration
Current Tissue Engineering (Discontinued) Clinical Considerations in Developing Dendritic Cell Vaccine Based Immunotherapy Protocols in Cancer
Current Molecular Medicine NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics Synthesis, Characterization and Evaluation of 1,3-Bisindolyl-2-Propen-1- One Derivatives as Potent Anti-Breast Cancer Agents
Current Bioactive Compounds Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Regenerative Potential of Stem Cell-derived Extracellular Vesicles in Spinal Cord Injury (SCI)
Current Stem Cell Research & Therapy Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents Disruptive Nanozyme Technology for Futuristic Bio-Medical and Bio-imaging Applications
Current Nanoscience Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Role of Biotransformation in Conceptal Toxicity of Drugs and Other Chemicals
Current Pharmaceutical Design Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design